SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after its ANKTIVA bladder cancer treatment received European Commission authorization, significantly expanding its global market. This news, combined with high short interest, is igniting community speculation about a massive short squeeze and increasing anticipation for further global approvals.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending after its recent earnings showed a significant EPS beat attributed largely to non-cash tax benefits, overshadowing an Adjusted EBITDA miss and fueling community concerns about "accounting magic" and opaque related-party dealings.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash rallied significantly after-hours following its latest earnings, which highlighted robust order growth and an optimistic marketplace outlook despite some estimate misses; this unexpected surge has ignited a fierce debate among investors, with many calling for a short squeeze against those who view the stock as overvalued.

B2Gold Corp. is an exploration company, which engages in the acquisition and development of mineral properties. It operates through the following segments: Fekola Mine, Fekola Regional, Masbate Mine, Otjikoto Mine, Goose Project, Other Mineral Properties, and Corporate and Other. The Fekola Regional segment consists of Bantako North, Menankoto, Dandoko, and Bakolobi properties. The Other Mineral Properties segment focuses on the company interests in mineral properties which are at various stages of exploration and evaluation. The Corporate and Other segment includes the corporate operations. The company was founded by Mark Anthony Corra, Thomas A. Garagan, Clive Thomas Johnson, and Roger Thomas Richer on November 30, 2006 and is headquartered in Vancouver, Canada.

B2gold Corp

B2Gold is trending following its recent earnings and 2026 guidance, sparking a polarized community debate where some investors see deep undervaluation amidst high gold prices, while others criticize management's execution and project outlook.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is trending after reporting a strong quarterly earnings beat and completing the sale of its chemical business to Berkshire Hathaway, which substantially strengthened its balance sheet. The community is actively discussing these fundamental improvements and the ongoing geopolitical tensions impacting global oil supply as potential tailwinds for the energy sector.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending as market participants debate how a proposed credit card interest rate cap could significantly benefit its merchant-funded, 0% interest buy-now-pay-later model, contrasting it sharply with traditional lenders. Despite its post-IPO struggles and current low valuation, many investors are highlighting Klarna's expanding partnerships and low default rates as reasons for a potential rebound.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways (CMPS) is trending following robust Phase 3 trial results for its COMP360 psilocybin therapy for treatment-resistant depression, which demonstrated highly significant efficacy, rapid onset, and impressive durability. This data is fueling community discussion about its potential as a pioneering FDA-approved psychedelic medicine, leading to analyst upgrades and overshadowing a recent share offering.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco is trending due to a significant partnership with the U.S. government and Brookfield to accelerate nuclear reactor deployment, a development seen by the community as vital for powering future AI growth and bolstering energy security. This initiative highlights Cameco's central role in the burgeoning nuclear energy renaissance and is driving widespread bullish sentiment despite some valuation concerns.

Purecycle Technologies, Inc. engages in recycling waste polypropylene into virgin polymer. Its process includes two steps: Feed Pre-Processing and the use of the Technology for purification. The company was founded by John Scott in September 2015 and is headquartered in Orlando, FL.

PureCycle Technologies Inc

PureCycle Technologies is trending following increased investment from Stanley Druckenmiller, a new board appointment from the Mars family, and recent announcements of capital raises and global expansion plans, which are sparking community debate between long-term growth potential and ongoing skepticism about immediate revenue.

ARK Investment Management LLC - ARK Innovation ETF

ARK Innovation ETF

ARKK is trending due to polarized community sentiment surrounding Cathie Wood's active portfolio adjustments, notably her continued buying of crypto-linked stocks like Coinbase and BitMine Immersion, alongside reducing exposure to names such as Tesla. Investors are debating if these actions signify high conviction in disruptive innovation or point to ongoing underperformance and capital destruction within the speculative growth sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MannKind (MNKD) to Release Earnings on Wednesday

MannKind (NASDAQ:MNKD) will be releasing its Q4 2025 earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration PR Newswire VANCOUVER...

MannKind (NASDAQ:MNKD) Receives Buy Rating from HC Wainwright

HC Wainwright reissued a "buy" rating and set a $11.00 price objective on shares of MannKind in a report on Monday...

Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets

Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets PR Newswire...

<ul class="summary-bullets"><li>The revised label provides clearer starting-dose guidance for adult patients switching from multiple daily injections or insulin pump therapy.</li><li>The update is supported by clinical results from the Dose Optimization study and the INHALE-3 trial.</li><li>Previously, MannKind filed a supplemental FDA application to expand Afrezza’s use to patients aged four to 17, with a decision anticipated by May 29, 2026.</li></ul>Shares of MannKind Corp. (MNKD) gained more than 7% in pre-market trading on Monday after the company announced that the U.S. Food and Drug Administration (FDA) approved an update to the prescribing information for Afrezza, its inhaled mealtime insulin used to improve glycemic control in adult patients with diabetes mellitus.The revised label provides clearer starting-dose guidance for adult patients switching from multiple daily injections or insulin pump therapy. The update is supported by clinical results from the Dose Optimization study and the INHALE-3 trial, which showed significantly improved post-meal glucose control after conversion to Afrezza, as recommended by the new dosing recommendations.“We expect that this label update will help support healthcare providers by providing clearer starting dose guidance when transitioning patients to inhaled insulin from subcutaneous mealtime insulin—whether injections or insulin pumps. We believe this refinement to the label helps support appropriate initiation of therapy while reinforcing Afrezza’s established clinical profile,” said Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Diabetes at MannKind Corporation.&nbsp;<h2 class="st-heading-2">Q3 Revenue Boosted By Afrezza Sales</h2>In November, the company posted a 17% increase in third-quarter (Q3) total revenue to $82.13 million, driven by strong growth in sales of its Afrezza inhaled insulin. Afrezza revenue climbed 23% to $18.5 million, supported by higher pricing and rising demand, while royalty income rose to $33.3 million.MannKind also submitted a supplemental application to the FDA seeking approval of Afrezza for patients aged four to 17. A regulatory decision is expected by May 29, 2026.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, accompanied by ‘high’ message volumes. MNKD was among the top trending tickers at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MNKD_jpg_fd37ecdc2d.webp" alt="MNKD.jpg" width="930" height="85"><figcaption>MNKD's Sentiment Meter and Message Volumes at Premarket on Jan. 26, 2026 | Source: Stocktwits</figcaption></figure>Meanwhile, one user didn’t see the FDA update as a major catalyst.<stembedurl>https://stocktwits.com/firefox2778/message/642859216</stembedurl>The stock has declined around 4.7% year-to-date and over 10.5% in the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ag-asml-hl-stocks-soar-silver-prices-record-high-110/cmy78kuR4WC">AG, ASM, HL Stocks Soar Pre-Market As Silver Blasts Past $110</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mannkind Corp and the company's inhalable insulin product. Company employee demonstrating how the device is used. (Photo by Lawrence K. Ho/Los Angeles Times via Getty Images)

Why Did MNKD Stock Jump Over 7% In Pre-Market Today?

The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.

MNKD Stock Gets A Pre-Market Boost From FDA Label Revision For Afrezza

Equity

Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema

IONS secures EU approval for Dawnzera in hereditary angioedema, after FDA clearance in the United States in August last year.

Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer

NVAX inks a non-exclusive Matrix-M license, securing $30M upfront, up to $500M in milestones and mid-single-digit royalties from Pfizer.

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.

Short Interest in MannKind Corporation (NASDAQ:MNKD) Grows By 26.1%

MannKind Corporation (NASDAQ:MNKD - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling...

Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease

FDA grants Breakthrough Therapy status to NVS's ianalumab for Sjogren's disease with plans for global filings starting in 2026.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $WMT earnings on Thursday?

Current Price	$5.44
Prev Close	$5.54
Open	$5.51
Dividend Yield	0.00%
50-Day Moving Average	$5.75
Beta	0.86
Avg. Volume	4.2M
PE Ratio	58.75

52-Week High	$6.51
52-Week Low	$3.38
Market Capitalization	$1.7B
EPS (Annual)	$0.0972
Price to Book	-38.18
Revenue Per Employee	$701,484.03

MNKD
Mannkind Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MNKD News

MNKDMannkind Corp